Safety and effectiveness of primary systemic therapy with docetaxel and trastuzumab in HER-2 positive breast cancer.

被引：0
|
作者：
Griggs, JJ [1 ]
Schiffhauer, LM [1 ]
Sahasrabudhe, DM [1 ]
Pandya, KJ [1 ]
Caldwell, C [1 ]
Peacock, J [1 ]
Messina, P [1 ]
Spreng, E [1 ]
Bourne, P [1 ]
McGuire, GM [1 ]
机构：
[1] Univ Rochester, Rochester, NY 14627 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：76S / 76S
页数：1
相关论文
共 50 条
  • [1] Predictors of response to primary systemic therapy (PST) with docetaxel and trastuzumab in HER2-positive breast cancer
    Rao, M.
    Griggs, J. J.
    Schiffhauer, L. M.
    Messina, P.
    Bourne, P.
    Ahrendt, G. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] Trastuzumab and oral vinorelbine (±endocrine therapy) as primary therapy in patients (pts) with HER-2/neu positive breast cancer.
    Torrisi, R.
    Magni, E.
    Dellapasqua, S.
    D'Alessandro, C.
    Veronesi, P.
    Luini, A.
    Minchella, I
    Ghisini, R.
    Nole, F.
    Viale, G.
    Goldhirsch, A.
    Colleoni, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S148 - S148
  • [3] Docetaxel, cyclophosphamide and trastuzumab as neoadjuvant chemotherapy in HER2-positive primary breast cancer.
    Nakatsukasa, Katsuhiko
    Taguchi, Tetsuya
    Sugimoto, Riho
    Sakaguchi, Kouichi
    Kotani, Tatsuya
    Hukuda, Kenichirou
    Kawakami, Sadao
    Hujiwara, Ikuya
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients
    Vici, P.
    Viola, G.
    Botti, C.
    Rossi, S.
    Vitucci, C.
    Corsetti, S.
    Di Lauro, L.
    Sergi, D.
    Foggi, P.
    Perri, P.
    Tirellil, C.
    Mottolese, M.
    Fattoruso, S. I. S.
    Lopez, M.
    CLINICA TERAPEUTICA, 2008, 159 (06): : 449 - 452
  • [5] Cardiac safety of docetaxel/cyclophosphamide/trastuzumab (DCH) as adjuvant therapy for HER-2 (+) early stage breast cancer
    Mato, A.
    Cappa, M.
    Fox, K.
    Policarpo, G.
    Cohen, J.
    Wall, H.
    Rossi, S.
    Mintzer, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [6] A multicenter, phase II study of epirubicin/cyclophosphamide followed by docetaxel and concurrent trastuzumab as primary systemic therapy for HER-2 positive advanced breast cancer (the HER2NAT study)
    Kenjiro Aogi
    Toshiaki Saeki
    Seigo Nakamura
    Masahiro Kashiwaba
    Nobuaki Sato
    Norikazu Masuda
    Yoshiaki Rai
    Shinji Ohno
    Katsumasa Kuroi
    Reiki Nishimura
    Keiko Miyakoda
    Futoshi Akiyama
    Masafumi Kurosumi
    Tadashi Ikeda
    International Journal of Clinical Oncology, 2013, 18 : 598 - 606
  • [7] A multicenter, phase II study of epirubicin/cyclophosphamide followed by docetaxel and concurrent trastuzumab as primary systemic therapy for HER-2 positive advanced breast cancer (the HER2NAT study)
    Aogi, Kenjiro
    Saeki, Toshiaki
    Nakamura, Seigo
    Kashiwaba, Masahiro
    Sato, Nobuaki
    Masuda, Norikazu
    Rai, Yoshiaki
    Ohno, Shinji
    Kuroi, Katsumasa
    Nishimura, Reiki
    Miyakoda, Keiko
    Akiyama, Futoshi
    Kurosumi, Masafumi
    Ikeda, Tadashi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2013, 18 (04) : 598 - 606
  • [8] Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer
    Gonzalez-Angulo, Ana M.
    Hortobagyi, Gabriel N.
    Esteva, Francisco J.
    ONCOLOGIST, 2006, 11 (08): : 857 - 867
  • [9] A multicenter phase II study of primary systemic therapy epirubicin/cyclophosphamide followed by docetaxel plus concurrent trastuzumab for HER2-positive advanced breast cancer.
    Saeki, T.
    Aogi, K.
    Nakamura, S.
    Kashiwaba, M.
    Sato, N.
    Masuda, N.
    Rai, Y.
    Ohno, S.
    Miyakoda, K.
    Ikeda, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [10] TRASTUZUMAB FOR BREAST CANCER OVEREXPRESSING HER-2: EVIDENCE OF EFFECTIVENESS, SAFETY AND COST ESTIMATION
    Alvares, J.
    Mata, A. D.
    Guerra Junior, A. A.
    Acurcio, F. A.
    VALUE IN HEALTH, 2013, 16 (07) : A682 - A682
12345